| 生物活性： |
背景说明：NBI-6024，一种变构肽配体 (APL)，是 1 型糖尿病患者中产生炎症性干扰素-γ 的 T 辅助淋巴细胞识别的表位。
In Vivo：NBI-6024 (0.005-20 mg/kg， s.c.) delays the onset and reduces the incidence of diabetes in mice.
参考文献：[1]. D G Alleva et al. Immunomodulation in type 1 diabetes by NBI-6024， an altered peptide ligand of the insulin B epitope. Scand J Immunol. 2006 Jan;63(1):59-69.
[2]. Alleva DG， et al. Immunological characterization and therapeutic activity of an altered-peptide ligand， NBI-6024， based on the immunodominant type 1 diabetes autoantigen insulin B-chain (9-23) peptide. Diabetes. 2002 Jul;51(7):2126-34.
|
扫一扫关注我们
